Clinical Trials Logo

Idiopathic Pulmonary Fibrosis clinical trials

View clinical trials related to Idiopathic Pulmonary Fibrosis.

Filter by:

NCT ID: NCT05870956 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

Start date: May 16, 2023
Phase:
Study type: Observational

This study has two objectives: 1. To assess the association between nintedanib adherence trajectory group (as measured from a Group-based Trajectory Modelling (GBTM)) and health care resource use, with a focus on inpatient hospitalization, among patients with Idiopathic Pulmonary Fibrosis (IPF). 2. To assess the association between a patient's nintedanib adherence trajectory group (as measured from a GBTM) and their medical costs among patients with IPF.

NCT ID: NCT05863091 Recruiting - Asthma Clinical Trials

Respiratory Rate Validation Study - HiCardi+ Wearable Patch Device, Mezoo Co., Ltd.

Start date: March 9, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze the accuracy of respiratory and breathing patterns generated through impedance changes generated by a patch-type electrocardiogram device (HiCardi+ wearable patch device, Mezoo Co., Ltd.), targeting patients undergoing pulmonary function testing and ventilator application.

NCT ID: NCT05842681 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Azithromycin in the Management of Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

The study will assess the role of using azithromycin in managing acute exacerbation of Idiopathic pulmonary fibrosis

NCT ID: NCT05828953 Recruiting - Clinical trials for Interstitial Lung Diseases

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Start date: September 28, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with FVC as the primary efficacy endpoint to evaluate its effectivenes

NCT ID: NCT05817240 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects

Start date: May 3, 2023
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed together in healthy subjects. Participants in this study will receive ENV-101 and/or nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site.

NCT ID: NCT05785624 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmonary fibrosis (IPF) and in participants with systemic sclerosis-associated interstitial lung disease (SSc-ILD). Participants who complete 52-weeks of treatment in the Double-blind Treatment (DBT) period can choose to enroll in the optional Open-label Extension (OLE) period to receive treatment with vixarelimab for another 52 weeks.

NCT ID: NCT05784207 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

An In Silico Trial to Evaluate Prospectively the Performance of a Radiomics Algorithm for UIP Compared to Medical Doctors

Start date: June 1, 2017
Phase:
Study type: Observational

The purpose of this study is to compare AI performance to doctor's performance in the evaluation of IPF/UIP and ILDs without UIP(proven by biopsy).

NCT ID: NCT05779007 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Dose Reduction and Discontinuation With Anti-Fibrotic Medications

Start date: April 18, 2023
Phase:
Study type: Observational

The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.

NCT ID: NCT05755308 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Faecal Microbiota Transplantation to Ameliorate Nintedanib-induced Diarrhea in Patients With Idiopathic Pulmonary Fibrosis

BIOFEV
Start date: October 2023
Phase: N/A
Study type: Interventional

This is a multicentric, randomised, double-blind, placebo-controlled study that will consist of two consecutive phases: 1. First phase: faecal samples will be collected in patients diagnosed with Idiopathic pulmonary fibrosis treated with nintedanib. 2. Second phase: double-blind, randomised, clinical trial of autologous faecal microbiota transplantation (FMT) vs placebo in Idiopathic pulmonary fibrosis patients who will experience nintedanib-induced diarrhea within 8 weeks of baseline visit. Follow-up visits will be scheduled at 1, 4 and 12 weeks after randomization. The main aim of the study is to assess the efficacy of FMT in ameliorating diarrhea experienced by patients with idiopathic pulmonary fibrosis treated with nintedanib.

NCT ID: NCT05722964 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis

Start date: March 29, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of intravenous SHR-1906 in the treatment of idiopathic pulmonary fibrosis. The study is divided into four stages: screening period, baseline period, treatment period and safe follow-up period. It is planned that 108 patients will be randomly assigned to the following three treatment groups for treatment